Physician profile
Jared Deck
NPI 1033609730
$1,771.68
in general payments reported to CMS, 2019-2025
23 companies · $744 in 2025
The $744 reported for 2025 was more than what 80% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $296 · 2024: $732 · 2025: $744.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,727 · Education: $44.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,726.75 |
| Education | $44.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $274.71 | 2023-2025 | Rybrevant, Erleada, Darzalex |
| Merck Sharp & Dohme LLC | $222.66 | 2024-2025 | Keytruda, Keytruda Qlex, Welireg |
| Abbvie INC. | $179.19 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $132.52 | 2024-2025 | Fruzaqla, Ninlaro |
| Ethicon INC. | $129.74 | 2023 | Monarch Platform |
| Reflexion Medical, INC. | $100.00 | 2023-2024 | Reflexion Medical Radiotherapy System |
| Novocure INC. | $93.31 | 2023 | Optune |
| Geron Corporation | $75.02 | 2024-2025 | Rytelo |
| Astrazeneca Pharmaceuticals Lp | $71.08 | 2024-2025 | Tagrisso |
| Karyopharm Therapeutics INC. | $61.67 | 2024-2025 | Xpovio |
| Sumitomo Pharma America, INC. | $59.51 | 2024 | Orgovyx |
| Incyte Corporation | $49.36 | 2024-2025 | Pemazyre, Monjuvi |
| Pfizer INC. | $46.36 | 2025 | |
| Novartis Pharmaceuticals Corporation | $41.11 | 2024-2025 | |
| Puma Biotechnology, INC. | $38.70 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $34.38 | 2024-2025 | Xtandi, Padcev |
| Bayer Healthcare Pharmaceuticals INC. | $28.52 | 2024 | |
| Tersera Therapeutics LLC | $28.01 | 2025 | Zoladex |
| Genentech USA, INC. | $24.49 | 2024 | Phesgo, Tecentriq, Perjeta |
| Pharmacosmos Therapeutics INC. | $22.99 | 2024 | Monoferric |
| Telix Pharmaceuticals | $22.91 | 2024 | Illuccix |
| Jazz Pharmaceuticals INC. | $19.77 | 2025 | |
| Springworks Therapeutics, INC. | $15.67 | 2025 | Ogsiveo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Deck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.